FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2345395671> ?p ?o ?g. }

• W2345395671 endingPage "251" @default.
• W2345395671 startingPage "251" @default.
• W2345395671 abstract "Sir, In the present study, we described the first case series of intraoperative positioning of subconjunctival dexamethasone implant as adjunctive antiscarring agent in patients undergone trabeculectomy for primary open angle glaucoma (POAG). The rationale of subconjunctival dexamethasone implant injection was to reduce the postsurgical overscarring at the site of the bleb, by limiting the first acute inflammatory reaction that represents the primum movens for conjunctival healing. Three eyes of three consecutive patients (three female) with a mean age of 61 ± 14.5 years taking a maximum tolerated dose of intraocular pressure (IOP)-lowering medication for POAG with a recorded IOP of ≥18 mmHg, glaucomatous damage on visual field and underwent trabeculectomy: All patients underwent a limbus-based conjunctival flap with one circumferential and one radial incision, antimetabolite sponge application, and scleral rectangular flap which was sutured with 10-0 nylon suture, sclerostomy with punch a peripheral iridectomy. Before the conjunctival suture with 9-0 vicryl was performed, a subconjunctival apposition without fixation of 0.7 mg sustained-release dexamethasone implant (Ozurdex, Allergan, Inc., Irvine, USA) was obtained. The implant was softly leaned on the sclera posterior to the flap. After 7 days, 1 month, and 2 months, the implant seemed to fragment reducing progressively its dimensions and was no more detectable after 2 months in all eyes [Fig. 1].Figure 1: Patient with primary open angle glaucoma undergone trabeculectomy and subconjunctival apposition of 0.7 mg sustained-release dexamethasone implant at day 1 (a), day 7 (b), month 1 (c), and month 2 (d). The implant seemed to fragment reducing progressively its dimensions and was no more detectable after 2 monthsAfter 2 months, IOP not quite significantly (P = 0.056, nonparametric Mann–Whitney U-test) decreased from 19.3 ± 2.3 mmHg (median: 18, interquartile range [IQR]: 4) at baseline to 15.7 ± 0.6 mmHg (median: 16, IQR: 1) without any glaucoma medication. In all eyes, IOP was ≤16 mmHg (range: 15–16). After 2 months in all the cases, conjunctival scarring at the site of the filtering bleb was not observed. No ocular adverse event or postoperative complications were observed. Corticosteroids have long been used as inflammation modulators of posttrabeculectomy conjunctival healing with significantly success rates, since they act on vascular permeability, as well as white blood cell chemotaxis and function.[1] First evidence of steroids effects in glaucoma surgery came from Starita et al.,[23] who investigated the effects of topical and systemic steroids in a randomized prospective trial. They found that topical steroids significantly improved trabeculectomy outcome as compared to the group without steroids at 5 and 10 years. There are studies about the intraoperative subconjunctival injection of triamcinolone acetonide (TA) after bleb-forming filtration surgery.[4] TA injections appeared to be safe in both studies, with no significant adverse events, even if results of a randomized controlled trial about long-term clinical benefits in patients receiving intrableb TA against whom receiving topical steroids only, have not been published yet. The rationale of intraoperative subconjunctival corticosteroid injection was to find a more direct, sustained, and convenient mode of steroid delivery in the operated patients; moreover, the bulk of injected TA would also serve as a barrier between the inflamed conjunctiva and sclera, to avoid adherence in between. In this view, Ozurdex implant would be even more effective than TA, lasting longer and interposing a bigger volume in the conjunctival layers. Subconjunctival implant appears to be well tolerated by operated eyes. However, use of Ozurdex has been associated with several adverse events including posterior subcapsular cataract and a higher risk of eye infections;[5] reasonably, the most threatening glaucoma surgery success is eye pressure increase that may need supplementary IOP lowering medical therapy after trabeculectomy. Effective success of surgery should therefore be taken only several weeks after the operation, when the insert is completely reabsorbed. Limitations of this study were the small sample size and the absence of a control group. The data of this pilot study showed that no serious side effects were noted, subconjunctival Ozurdex was well tolerated and that a controlled study is required to establish the efficacy of this easy to perform the technique. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest." @default.
• W2345395671 created "2016-06-24" @default.
• W2345395671 creator A5015670101 @default.
• W2345395671 creator A5022174875 @default.
• W2345395671 creator A5043594191 @default.
• W2345395671 creator A5076942951 @default.
• W2345395671 creator A5087779305 @default.
• W2345395671 date "2016-01-01" @default.
• W2345395671 modified "2023-09-23" @default.
• W2345395671 title "Subconjunctival sustained-release dexamethasone implant as an adjunct to trabeculectomy for primary open angle glaucoma" @default.
• W2345395671 cites W1975620432 @default.
• W2345395671 cites W2006804172 @default.
• W2345395671 cites W2023417861 @default.
• W2345395671 cites W2023949975 @default.
• W2345395671 cites W2024776123 @default.
• W2345395671 doi "https://doi.org/10.4103/0301-4738.181735" @default.
• W2345395671 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4869472" @default.
• W2345395671 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27146944" @default.
• W2345395671 hasPublicationYear "2016" @default.
• W2345395671 type Work @default.
• W2345395671 sameAs 2345395671 @default.
• W2345395671 citedByCount "4" @default.
• W2345395671 countsByYear W23453956712019 @default.
• W2345395671 countsByYear W23453956712020 @default.
• W2345395671 countsByYear W23453956712023 @default.
• W2345395671 crossrefType "journal-article" @default.
• W2345395671 hasAuthorship W2345395671A5015670101 @default.
• W2345395671 hasAuthorship W2345395671A5022174875 @default.
• W2345395671 hasAuthorship W2345395671A5043594191 @default.
• W2345395671 hasAuthorship W2345395671A5076942951 @default.
• W2345395671 hasAuthorship W2345395671A5087779305 @default.
• W2345395671 hasBestOaLocation W23453956711 @default.
• W2345395671 hasConcept C105702510 @default.
• W2345395671 hasConcept C117866178 @default.
• W2345395671 hasConcept C118487528 @default.
• W2345395671 hasConcept C126322002 @default.
• W2345395671 hasConcept C141071460 @default.
• W2345395671 hasConcept C2776228307 @default.
• W2345395671 hasConcept C2777100477 @default.
• W2345395671 hasConcept C2777824320 @default.
• W2345395671 hasConcept C2778527774 @default.
• W2345395671 hasConcept C2780401358 @default.
• W2345395671 hasConcept C2781092963 @default.
• W2345395671 hasConcept C2781411149 @default.
• W2345395671 hasConcept C2991803831 @default.
• W2345395671 hasConcept C71924100 @default.
• W2345395671 hasConceptScore W2345395671C105702510 @default.
• W2345395671 hasConceptScore W2345395671C117866178 @default.
• W2345395671 hasConceptScore W2345395671C118487528 @default.
• W2345395671 hasConceptScore W2345395671C126322002 @default.
• W2345395671 hasConceptScore W2345395671C141071460 @default.
• W2345395671 hasConceptScore W2345395671C2776228307 @default.
• W2345395671 hasConceptScore W2345395671C2777100477 @default.
• W2345395671 hasConceptScore W2345395671C2777824320 @default.
• W2345395671 hasConceptScore W2345395671C2778527774 @default.
• W2345395671 hasConceptScore W2345395671C2780401358 @default.
• W2345395671 hasConceptScore W2345395671C2781092963 @default.
• W2345395671 hasConceptScore W2345395671C2781411149 @default.
• W2345395671 hasConceptScore W2345395671C2991803831 @default.
• W2345395671 hasConceptScore W2345395671C71924100 @default.
• W2345395671 hasIssue "3" @default.
• W2345395671 hasLocation W23453956711 @default.
• W2345395671 hasLocation W23453956712 @default.
• W2345395671 hasLocation W23453956713 @default.
• W2345395671 hasLocation W23453956714 @default.
• W2345395671 hasLocation W23453956715 @default.
• W2345395671 hasLocation W23453956716 @default.
• W2345395671 hasLocation W23453956717 @default.
• W2345395671 hasOpenAccess W2345395671 @default.
• W2345395671 hasPrimaryLocation W23453956711 @default.
• W2345395671 hasRelatedWork W2022049485 @default.
• W2345395671 hasRelatedWork W2051502178 @default.
• W2345395671 hasRelatedWork W2068363936 @default.
• W2345395671 hasRelatedWork W2081625686 @default.
• W2345395671 hasRelatedWork W2386574860 @default.
• W2345395671 hasRelatedWork W2416356040 @default.
• W2345395671 hasRelatedWork W2778096022 @default.
• W2345395671 hasRelatedWork W2911674918 @default.
• W2345395671 hasRelatedWork W3032208024 @default.
• W2345395671 hasRelatedWork W2247202974 @default.
• W2345395671 hasVolume "64" @default.
• W2345395671 isParatext "false" @default.
• W2345395671 isRetracted "false" @default.
• W2345395671 magId "2345395671" @default.
• W2345395671 workType "article" @default.